Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Squamous Cell | 8 | 2024 | 4025 | 2.020 |
Why?
|
Multiple Myeloma | 29 | 2024 | 5131 | 1.520 |
Why?
|
Skin Neoplasms | 8 | 2022 | 5796 | 1.360 |
Why?
|
Cyclin D1 | 2 | 2024 | 453 | 0.820 |
Why?
|
Chromosome Aberrations | 9 | 2023 | 1771 | 0.730 |
Why?
|
Neoplasm Staging | 6 | 2022 | 11123 | 0.700 |
Why?
|
Peripheral Nerves | 1 | 2020 | 473 | 0.550 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2019 | 685 | 0.480 |
Why?
|
Plasma Cells | 8 | 2017 | 591 | 0.470 |
Why?
|
High-Throughput Nucleotide Sequencing | 5 | 2019 | 3615 | 0.430 |
Why?
|
Sequence Analysis, RNA | 1 | 2020 | 1993 | 0.420 |
Why?
|
Neoplasms, Multiple Primary | 3 | 2021 | 586 | 0.400 |
Why?
|
Thalidomide | 5 | 2017 | 884 | 0.380 |
Why?
|
Paraproteinemias | 4 | 2016 | 246 | 0.380 |
Why?
|
Cyclin D2 | 2 | 2024 | 98 | 0.360 |
Why?
|
Mutation, Missense | 1 | 2019 | 2559 | 0.350 |
Why?
|
Prognosis | 21 | 2022 | 29561 | 0.350 |
Why?
|
Head and Neck Neoplasms | 1 | 2024 | 2876 | 0.330 |
Why?
|
Genome, Human | 2 | 2021 | 4412 | 0.310 |
Why?
|
Neoplasm Invasiveness | 3 | 2021 | 3619 | 0.300 |
Why?
|
Dexamethasone | 5 | 2020 | 1927 | 0.280 |
Why?
|
Colorectal Neoplasms | 6 | 2023 | 6853 | 0.270 |
Why?
|
DNA | 1 | 2019 | 7237 | 0.260 |
Why?
|
Gene Expression Profiling | 10 | 2024 | 9374 | 0.250 |
Why?
|
Syndecan-1 | 2 | 2018 | 163 | 0.250 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 5247 | 0.250 |
Why?
|
Gene Expression Regulation, Neoplastic | 13 | 2022 | 8491 | 0.240 |
Why?
|
Loss of Heterozygosity | 2 | 2020 | 659 | 0.240 |
Why?
|
DNA Copy Number Variations | 5 | 2021 | 2012 | 0.230 |
Why?
|
Neoplasm, Residual | 2 | 2022 | 1007 | 0.230 |
Why?
|
Cyclin D | 1 | 2024 | 72 | 0.230 |
Why?
|
In Situ Hybridization, Fluorescence | 4 | 2019 | 2499 | 0.220 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2019 | 3605 | 0.220 |
Why?
|
Gene Dosage | 4 | 2016 | 1218 | 0.220 |
Why?
|
Immunophenotyping | 7 | 2016 | 1870 | 0.210 |
Why?
|
DNA Methylation | 5 | 2022 | 4371 | 0.200 |
Why?
|
Algorithms | 2 | 2020 | 13946 | 0.200 |
Why?
|
Amiloride | 2 | 2022 | 116 | 0.200 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 2 | 2015 | 179 | 0.200 |
Why?
|
Chromosomes, Human | 2 | 2014 | 442 | 0.190 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2022 | 2925 | 0.190 |
Why?
|
KCNQ2 Potassium Channel | 1 | 2021 | 19 | 0.190 |
Why?
|
Breathing Exercises | 1 | 2021 | 60 | 0.190 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2022 | 124 | 0.190 |
Why?
|
Thrombocythemia, Essential | 1 | 2022 | 107 | 0.180 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 2022 | 167 | 0.180 |
Why?
|
Retrospective Studies | 9 | 2022 | 80121 | 0.180 |
Why?
|
Aged, 80 and over | 13 | 2022 | 58867 | 0.180 |
Why?
|
Carcinoma, Pancreatic Ductal | 3 | 2018 | 1708 | 0.180 |
Why?
|
Athletic Performance | 1 | 2021 | 105 | 0.180 |
Why?
|
Humans | 60 | 2024 | 759255 | 0.180 |
Why?
|
Osteogenesis | 2 | 2017 | 1268 | 0.170 |
Why?
|
Chromosome Breakpoints | 1 | 2019 | 93 | 0.170 |
Why?
|
Leukemia, Plasma Cell | 1 | 2019 | 46 | 0.170 |
Why?
|
DNA Mutational Analysis | 2 | 2019 | 4111 | 0.170 |
Why?
|
Lung Neoplasms | 1 | 2024 | 13238 | 0.170 |
Why?
|
Drug Synergism | 3 | 2017 | 1755 | 0.160 |
Why?
|
Serum Amyloid P-Component | 1 | 2018 | 46 | 0.160 |
Why?
|
Hematologic Neoplasms | 2 | 2022 | 1898 | 0.160 |
Why?
|
Nucleotidyltransferases | 1 | 2020 | 243 | 0.150 |
Why?
|
Mesenchymal Stem Cells | 2 | 2019 | 1630 | 0.150 |
Why?
|
Karyotyping | 1 | 2019 | 1177 | 0.150 |
Why?
|
Thiadiazoles | 1 | 2017 | 64 | 0.140 |
Why?
|
Antigens, CD34 | 1 | 2019 | 653 | 0.140 |
Why?
|
Tumor Burden | 2 | 2020 | 1886 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-pim-1 | 1 | 2016 | 32 | 0.140 |
Why?
|
Immunoglobulins | 1 | 2020 | 863 | 0.140 |
Why?
|
Telomere | 1 | 2023 | 934 | 0.140 |
Why?
|
Gamma Rays | 1 | 2017 | 316 | 0.140 |
Why?
|
RNA, Messenger | 5 | 2020 | 12774 | 0.130 |
Why?
|
Opportunistic Infections | 1 | 2018 | 377 | 0.130 |
Why?
|
MicroRNAs | 5 | 2020 | 3797 | 0.130 |
Why?
|
Tumor Cells, Cultured | 2 | 2020 | 6131 | 0.130 |
Why?
|
Protective Agents | 1 | 2016 | 150 | 0.130 |
Why?
|
Lectins, C-Type | 1 | 2018 | 591 | 0.130 |
Why?
|
Incidental Findings | 1 | 2020 | 699 | 0.130 |
Why?
|
Antibody Formation | 1 | 2020 | 1398 | 0.120 |
Why?
|
Immunoglobulin Light Chains | 1 | 2016 | 278 | 0.120 |
Why?
|
Adipogenesis | 1 | 2017 | 358 | 0.120 |
Why?
|
Sensitivity and Specificity | 2 | 2021 | 14652 | 0.120 |
Why?
|
Systems Integration | 1 | 2016 | 426 | 0.120 |
Why?
|
Genomics | 6 | 2016 | 5775 | 0.120 |
Why?
|
Immunoassay | 1 | 2018 | 748 | 0.120 |
Why?
|
Pancreaticoduodenectomy | 1 | 2018 | 506 | 0.120 |
Why?
|
Diuretics | 1 | 2017 | 612 | 0.120 |
Why?
|
Interphase | 1 | 2014 | 229 | 0.110 |
Why?
|
Aged | 20 | 2021 | 168617 | 0.110 |
Why?
|
Pancreatic Neoplasms | 3 | 2018 | 5310 | 0.110 |
Why?
|
Polymorphism, Single Nucleotide | 7 | 2021 | 15750 | 0.110 |
Why?
|
Meningioma | 1 | 2023 | 1217 | 0.110 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1790 | 0.110 |
Why?
|
Plasmacytoma | 1 | 2014 | 171 | 0.110 |
Why?
|
Meningeal Neoplasms | 1 | 2023 | 1245 | 0.110 |
Why?
|
Burkitt Lymphoma | 1 | 2015 | 333 | 0.110 |
Why?
|
Cell Line, Tumor | 10 | 2020 | 16871 | 0.110 |
Why?
|
Interleukin-8 | 1 | 2016 | 698 | 0.110 |
Why?
|
Phagocytosis | 1 | 2018 | 1535 | 0.110 |
Why?
|
RNA Processing, Post-Transcriptional | 1 | 2015 | 417 | 0.100 |
Why?
|
Nanotechnology | 1 | 2018 | 708 | 0.100 |
Why?
|
Male | 24 | 2022 | 358719 | 0.100 |
Why?
|
Drainage | 1 | 2018 | 1157 | 0.100 |
Why?
|
Developmental Disabilities | 1 | 2021 | 1502 | 0.100 |
Why?
|
Open Reading Frames | 1 | 2015 | 813 | 0.100 |
Why?
|
Rectal Neoplasms | 1 | 2021 | 1152 | 0.100 |
Why?
|
Myelodysplastic Syndromes | 1 | 2022 | 1395 | 0.100 |
Why?
|
Cytogenetic Analysis | 3 | 2022 | 271 | 0.100 |
Why?
|
RNA, Untranslated | 1 | 2015 | 459 | 0.100 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2016 | 611 | 0.100 |
Why?
|
Bone Marrow Cells | 1 | 2019 | 2424 | 0.100 |
Why?
|
Female | 24 | 2022 | 390240 | 0.090 |
Why?
|
Genetic Predisposition to Disease | 4 | 2021 | 17750 | 0.090 |
Why?
|
Antineoplastic Agents | 3 | 2022 | 13621 | 0.090 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2016 | 707 | 0.090 |
Why?
|
Protein Kinase Inhibitors | 2 | 2016 | 5635 | 0.090 |
Why?
|
Pilot Projects | 1 | 2022 | 8540 | 0.080 |
Why?
|
Bone Marrow | 1 | 2019 | 2918 | 0.080 |
Why?
|
Amyloidosis | 1 | 2016 | 815 | 0.080 |
Why?
|
Phenotype | 8 | 2021 | 16532 | 0.080 |
Why?
|
Flow Cytometry | 3 | 2015 | 5870 | 0.080 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2016 | 5214 | 0.080 |
Why?
|
Risk | 1 | 2021 | 9623 | 0.080 |
Why?
|
Sequence Analysis, DNA | 1 | 2019 | 4716 | 0.080 |
Why?
|
Early Detection of Cancer | 1 | 2023 | 3204 | 0.080 |
Why?
|
Base Sequence | 1 | 2019 | 12450 | 0.080 |
Why?
|
Hematopoiesis | 1 | 2017 | 2063 | 0.080 |
Why?
|
Immunotherapy | 1 | 2024 | 4622 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2016 | 2448 | 0.070 |
Why?
|
Computational Biology | 2 | 2016 | 3505 | 0.070 |
Why?
|
B-Lymphocytes | 3 | 2017 | 4733 | 0.070 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2016 | 2061 | 0.070 |
Why?
|
Chromosomes, Human, Pair 11 | 2 | 2020 | 410 | 0.070 |
Why?
|
Middle Aged | 18 | 2023 | 219653 | 0.070 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2016 | 2866 | 0.070 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2022 | 9269 | 0.070 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2017 | 2867 | 0.070 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 1524 | 0.070 |
Why?
|
C-Reactive Protein | 1 | 2018 | 3823 | 0.070 |
Why?
|
Gene Frequency | 3 | 2020 | 3603 | 0.070 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2013 | 937 | 0.070 |
Why?
|
Skin | 1 | 2020 | 4467 | 0.070 |
Why?
|
Ikaros Transcription Factor | 2 | 2020 | 231 | 0.070 |
Why?
|
Bone and Bones | 1 | 2016 | 2560 | 0.060 |
Why?
|
Lymphocyte Activation | 1 | 2016 | 5497 | 0.060 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2015 | 1067 | 0.060 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2015 | 2824 | 0.060 |
Why?
|
Comparative Genomic Hybridization | 2 | 2016 | 473 | 0.060 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15264 | 0.060 |
Why?
|
Membrane Proteins | 1 | 2021 | 7851 | 0.060 |
Why?
|
Graft vs Host Disease | 1 | 2016 | 3022 | 0.060 |
Why?
|
Risk Factors | 6 | 2022 | 74167 | 0.060 |
Why?
|
CpG Islands | 2 | 2021 | 1221 | 0.060 |
Why?
|
Translocation, Genetic | 2 | 2022 | 1388 | 0.050 |
Why?
|
Melphalan | 2 | 2016 | 421 | 0.050 |
Why?
|
Cell Differentiation | 2 | 2017 | 11476 | 0.050 |
Why?
|
Monosomy | 1 | 2023 | 52 | 0.050 |
Why?
|
Propidium | 1 | 2022 | 42 | 0.050 |
Why?
|
Annexin A5 | 1 | 2022 | 103 | 0.050 |
Why?
|
Alternative Splicing | 2 | 2019 | 1091 | 0.050 |
Why?
|
Osteoclasts | 2 | 2016 | 712 | 0.050 |
Why?
|
Cell Survival | 3 | 2017 | 5796 | 0.050 |
Why?
|
Clone Cells | 2 | 2016 | 1663 | 0.050 |
Why?
|
Microarray Analysis | 2 | 2016 | 748 | 0.050 |
Why?
|
Cytogenetics | 1 | 2022 | 198 | 0.050 |
Why?
|
Cell Proliferation | 4 | 2020 | 10440 | 0.050 |
Why?
|
Coculture Techniques | 2 | 2016 | 1335 | 0.050 |
Why?
|
Epigenesis, Genetic | 1 | 2014 | 3754 | 0.050 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2016 | 3774 | 0.050 |
Why?
|
Risk Assessment | 1 | 2022 | 24049 | 0.050 |
Why?
|
Prospective Studies | 2 | 2024 | 54204 | 0.050 |
Why?
|
Cluster Analysis | 2 | 2021 | 2698 | 0.050 |
Why?
|
Respiratory Muscles | 1 | 2021 | 142 | 0.050 |
Why?
|
Liver Neoplasms | 1 | 2016 | 4312 | 0.050 |
Why?
|
Respiratory Therapy | 1 | 2021 | 127 | 0.050 |
Why?
|
Treatment Outcome | 6 | 2018 | 64879 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 3 | 2016 | 6532 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2017 | 11653 | 0.040 |
Why?
|
Apoptosis | 4 | 2017 | 9492 | 0.040 |
Why?
|
Disease Progression | 5 | 2016 | 13479 | 0.040 |
Why?
|
Chromosomal Instability | 1 | 2021 | 177 | 0.040 |
Why?
|
Stromal Cells | 2 | 2016 | 1327 | 0.040 |
Why?
|
Gene Duplication | 1 | 2021 | 314 | 0.040 |
Why?
|
Cell Separation | 2 | 2016 | 1724 | 0.040 |
Why?
|
Genes, p53 | 1 | 2022 | 714 | 0.040 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2020 | 375 | 0.040 |
Why?
|
Caspases | 1 | 2022 | 878 | 0.040 |
Why?
|
Interferon Regulatory Factors | 1 | 2020 | 260 | 0.040 |
Why?
|
Polyadenylation | 1 | 2020 | 118 | 0.040 |
Why?
|
Genetic Association Studies | 2 | 2019 | 2712 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2017 | 3584 | 0.040 |
Why?
|
Unfolded Protein Response | 1 | 2020 | 233 | 0.040 |
Why?
|
Survival Rate | 3 | 2018 | 12800 | 0.040 |
Why?
|
Dystonia | 1 | 2021 | 364 | 0.040 |
Why?
|
Mutation | 5 | 2021 | 29877 | 0.040 |
Why?
|
Protein Isoforms | 1 | 2022 | 1695 | 0.040 |
Why?
|
Microsatellite Instability | 1 | 2021 | 715 | 0.040 |
Why?
|
Signal Transduction | 5 | 2020 | 23362 | 0.040 |
Why?
|
Receptors, Purinergic P2Y | 1 | 2016 | 24 | 0.040 |
Why?
|
Gene Knockout Techniques | 1 | 2020 | 803 | 0.030 |
Why?
|
Cohort Studies | 1 | 2019 | 41247 | 0.030 |
Why?
|
Aspergillosis | 1 | 2018 | 243 | 0.030 |
Why?
|
Up-Regulation | 2 | 2016 | 4132 | 0.030 |
Why?
|
Cell Cycle | 2 | 2016 | 2939 | 0.030 |
Why?
|
LDL-Receptor Related Proteins | 1 | 2016 | 118 | 0.030 |
Why?
|
Cell Dedifferentiation | 1 | 2017 | 121 | 0.030 |
Why?
|
Genes, Tumor Suppressor | 1 | 2020 | 1056 | 0.030 |
Why?
|
Cerebral Palsy | 1 | 2021 | 471 | 0.030 |
Why?
|
Glycosyltransferases | 1 | 2016 | 118 | 0.030 |
Why?
|
Candidiasis | 1 | 2018 | 363 | 0.030 |
Why?
|
Adult | 10 | 2021 | 219390 | 0.030 |
Why?
|
Cyclin D3 | 1 | 2015 | 54 | 0.030 |
Why?
|
Motor Neurons | 1 | 2021 | 864 | 0.030 |
Why?
|
Mice | 6 | 2019 | 81138 | 0.030 |
Why?
|
E-Box Elements | 1 | 2014 | 20 | 0.030 |
Why?
|
Exons | 1 | 2021 | 2389 | 0.030 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 2015 | 286 | 0.030 |
Why?
|
Thiophenes | 1 | 2019 | 587 | 0.030 |
Why?
|
Genes, Neoplasm | 1 | 2016 | 370 | 0.030 |
Why?
|
Synaptic Transmission | 1 | 2021 | 1169 | 0.030 |
Why?
|
Protein Processing, Post-Translational | 1 | 2022 | 1972 | 0.030 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2020 | 1314 | 0.030 |
Why?
|
Tumor Stem Cell Assay | 1 | 2013 | 115 | 0.030 |
Why?
|
Age of Onset | 1 | 2021 | 3301 | 0.030 |
Why?
|
Promoter Regions, Genetic | 2 | 2015 | 5789 | 0.030 |
Why?
|
Antifungal Agents | 1 | 2018 | 745 | 0.030 |
Why?
|
Precursor Cells, B-Lymphoid | 1 | 2014 | 98 | 0.030 |
Why?
|
Morpholines | 1 | 2016 | 582 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2018 | 12152 | 0.030 |
Why?
|
3' Untranslated Regions | 1 | 2015 | 522 | 0.030 |
Why?
|
Aminopyridines | 1 | 2016 | 564 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2019 | 1408 | 0.030 |
Why?
|
Animals | 7 | 2019 | 167838 | 0.030 |
Why?
|
Standard of Care | 1 | 2016 | 551 | 0.030 |
Why?
|
Bone Resorption | 1 | 2016 | 720 | 0.030 |
Why?
|
United States | 1 | 2020 | 72237 | 0.020 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 616 | 0.020 |
Why?
|
Principal Component Analysis | 1 | 2014 | 938 | 0.020 |
Why?
|
Integrins | 1 | 2016 | 840 | 0.020 |
Why?
|
Quinolines | 1 | 2016 | 758 | 0.020 |
Why?
|
Prednisone | 1 | 2016 | 1562 | 0.020 |
Why?
|
Membrane Transport Proteins | 1 | 2016 | 1035 | 0.020 |
Why?
|
Demography | 1 | 2015 | 1648 | 0.020 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2015 | 581 | 0.020 |
Why?
|
Nucleic Acid Hybridization | 1 | 2012 | 1304 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2014 | 2015 | 0.020 |
Why?
|
Imidazoles | 1 | 2016 | 1175 | 0.020 |
Why?
|
Immunoglobulin M | 1 | 2015 | 1529 | 0.020 |
Why?
|
Family | 1 | 2021 | 3189 | 0.020 |
Why?
|
Boronic Acids | 1 | 2014 | 914 | 0.020 |
Why?
|
Databases, Genetic | 1 | 2016 | 1740 | 0.020 |
Why?
|
Cell Adhesion Molecules | 1 | 2016 | 1600 | 0.020 |
Why?
|
Genetic Markers | 1 | 2016 | 2608 | 0.020 |
Why?
|
Sulfonamides | 1 | 2019 | 1972 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2020 | 4883 | 0.020 |
Why?
|
Benzimidazoles | 1 | 2014 | 858 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 3804 | 0.020 |
Why?
|
Mice, SCID | 1 | 2014 | 2628 | 0.020 |
Why?
|
Preoperative Care | 1 | 2018 | 2256 | 0.020 |
Why?
|
T-Lymphocytes | 2 | 2016 | 10181 | 0.020 |
Why?
|
Down-Regulation | 1 | 2016 | 2920 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2020 | 4491 | 0.020 |
Why?
|
Transplantation, Autologous | 1 | 2013 | 2120 | 0.020 |
Why?
|
Polymorphism, Genetic | 1 | 2018 | 4286 | 0.020 |
Why?
|
Pyrazines | 1 | 2014 | 1201 | 0.020 |
Why?
|
Seizures | 1 | 2021 | 2908 | 0.020 |
Why?
|
RNA Interference | 1 | 2016 | 2847 | 0.020 |
Why?
|
Cell Movement | 1 | 2020 | 5209 | 0.020 |
Why?
|
Genome | 1 | 2015 | 1739 | 0.020 |
Why?
|
Remission Induction | 1 | 2013 | 2388 | 0.020 |
Why?
|
Doxorubicin | 1 | 2014 | 2203 | 0.020 |
Why?
|
Survival Analysis | 1 | 2020 | 10185 | 0.020 |
Why?
|
Pyrimidines | 1 | 2019 | 2996 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2016 | 6070 | 0.020 |
Why?
|
Genome-Wide Association Study | 2 | 2016 | 12580 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2015 | 2198 | 0.020 |
Why?
|
Child | 3 | 2021 | 79623 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2016 | 18110 | 0.020 |
Why?
|
Neoplastic Stem Cells | 1 | 2014 | 1344 | 0.020 |
Why?
|
Young Adult | 3 | 2018 | 58483 | 0.020 |
Why?
|
Models, Genetic | 1 | 2016 | 3443 | 0.020 |
Why?
|
Phosphorylation | 1 | 2016 | 8313 | 0.020 |
Why?
|
Epilepsy | 1 | 2021 | 3260 | 0.020 |
Why?
|
Trans-Activators | 1 | 2014 | 2860 | 0.010 |
Why?
|
Child, Preschool | 2 | 2018 | 41935 | 0.010 |
Why?
|
Incidence | 1 | 2023 | 21336 | 0.010 |
Why?
|
Recurrence | 1 | 2016 | 8469 | 0.010 |
Why?
|
Adolescent | 3 | 2018 | 87560 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2014 | 6496 | 0.010 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2014 | 2896 | 0.010 |
Why?
|
Chromosome Mapping | 1 | 2012 | 4625 | 0.010 |
Why?
|
Gene Expression | 1 | 2016 | 7593 | 0.010 |
Why?
|
Antigens, CD | 1 | 2013 | 4000 | 0.010 |
Why?
|
Lung | 1 | 2021 | 9982 | 0.010 |
Why?
|
Circadian Rhythm | 1 | 2013 | 2567 | 0.010 |
Why?
|
Genotype | 1 | 2016 | 12940 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2017 | 18968 | 0.010 |
Why?
|
Nerve Tissue Proteins | 1 | 2014 | 4409 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12522 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2013 | 8549 | 0.010 |
Why?
|
Follow-Up Studies | 2 | 2013 | 39216 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2015 | 14442 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2016 | 26109 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2013 | 21988 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2013 | 20031 | 0.010 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2013 | 5630 | 0.010 |
Why?
|
Time Factors | 1 | 2016 | 40109 | 0.010 |
Why?
|
Infant | 1 | 2016 | 35941 | 0.010 |
Why?
|